Bilirubin Reagent Kit (Total and Direct — DPD Method, Clinical Biochemistry)

The DPD (3,5-dichlorophenyl diazonium tetrafluoroborate) method is a photometric colorimetric bilirubin assay in which the diazonium salt in Reagent 2 reacts with bilirubin under acidic conditions to form a coloured azobilirubin compound measured at 540nm. The Jendrassik-Grof method uses a different diazonium reagent (sulphanilic acid + nitrite) and requires a separate reagent for total vs direct bilirubin measurement, with a caffeine-tartrate accelerator for total bilirubin. The DPD method advantages for automated clinical laboratory use include: a simpler two-reagent (R1/R2) format directly compatible with standard clinical chemistry analyser reagent loading; liquid ready-to-use formulation without preparation steps; stable opened reagents on board analysers (up to 90 days in some formulations); and good analytical correlation with reference methods traceable to NIST SRM 916a bilirubin standard. The Jendrassik-Grof method is still used in manual spectrophotometry and some semi-automated settings.

The recommended specimen type for bilirubin measurement is fresh, non-haemolysed serum — collected in a serum separator tube (SST, gold top) or plain red tube. EDTA or heparin plasma are also acceptable for most bilirubin methods. The critical pre-analytical requirement is light protection: bilirubin is highly photolabile and degrades significantly with exposure to daylight or fluorescent light. Blood tubes and specimens for bilirubin testing must be wrapped in foil or kept in a dark container from collection to analysis. Key interferences include: haemolysis (haemoglobin interferes with the 540nm measurement producing falsely low or false high results depending on method); lipaemia (turbidity interferes with photometric reading); medications including rifampicin (can produce false elevations); and indocyanine green (incompatible with Roche TBIL method). Each reagent kit's package insert specifies the interference limits for the specific method.

Reference ranges for bilirubin vary by age, particularly in the neonatal period. In adults, the typical reference range is: Total Bilirubin: 0.2-1.2 mg/dL (3.4-20.5 µmol/L); Direct (conjugated) Bilirubin: 0.0-0.3 mg/dL (0-5.1 µmol/L); Indirect (unconjugated) Bilirubin (calculated): 0.2-0.9 mg/dL. Clinical jaundice (yellow colouration of skin and eyes) becomes visible when total bilirubin exceeds approximately 2-3 mg/dL. In neonates, bilirubin levels rise physiologically in the first few days of life as the immature liver processes fetal haemoglobin breakdown products — neonatal bilirubin reference ranges are age-in-hours-specific and are interpreted using nomograms (Bhutani nomogram) or specific phototherapy threshold charts rather than simple adult ranges. Each laboratory should establish and verify its own reference intervals per CLSI EP28-A3c guidelines.

Bilirubin reagent kits should be stored refrigerated at 2-8°C throughout the supply chain and in the laboratory. They must not be frozen — confirmed from multiple reagent package inserts (DPD method: do not freeze; R1 and R2 stored at 2-8°C). The reagents are stable unopened until the expiry date printed on the label when stored at 2-8°C. Once opened and placed on board an automated analyser or in an open reagent position, stability varies by formulation — the DPD method (Beckman Coulter reference, CDC NHANES method document) specifies 90 days on-board stability at 2-8°C on the analyser. Light exposure must be minimised — both in storage and during reagent handling. If the reagent shows cloudiness or precipitation, it should be discarded as this indicates deterioration that will produce unreliable results.

Bilirubin reagent kits require calibration against a certified calibrator traceable to an authoritative reference standard. For DPD-method bilirubin, calibration traceability to NIST Standard Reference Material (SRM) 916a is the reference standard — confirmed from Beckman Coulter bilirubin assay documentation (NHANES CDC methodology). Calibration must be performed when: a new reagent lot is placed into use; a new calibrator lot is used; after major preventative maintenance or critical component replacement on the analyser; when quality control (QC) results fall outside acceptable limits; or after the on-board stability period of the calibration. Quality control samples (both normal and abnormal concentrations) should be run at minimum once per shift or per CLSI QC guidelines. Calibrator values must be assigned by the reagent manufacturer and should not be substituted between different manufacturer's reagent systems.